Cargando…
The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma
SIMPLE SUMMARY: Immune checkpoint inhibitors (ICIs) have significantly changed the treatment paradigm in metastatic renal cell carcinoma (mRCC) and brought an unprecedented durable response. However, there is still a significant proportion of patients who do not response to ICIs, and there are no bi...
Autores principales: | Chen, Yu-Wei, Tucker, Matthew D., Brown, Landon C., Yasin, Hesham A., Ancell, Kristin K., Armstrong, Andrew J., Beckermann, Kathryn E., Davis, Nancy B., Harrison, Michael R., Kaiser, Elizabeth G., McAlister, Renee K., Schaffer, Kerry R., Wallace, Deborah E., George, Daniel J., Rathmell, W. Kimryn, Rini, Brian I., Zhang, Tian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367298/ https://www.ncbi.nlm.nih.gov/pubmed/35954493 http://dx.doi.org/10.3390/cancers14153830 |
Ejemplares similares
-
Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma
por: Tucker, Matthew D., et al.
Publicado: (2021) -
Eosinophilic airway inflammation and eosinophilic chronic rhinosinusitis during nivolumab and ipilimumab
por: Watanabe, Hirofumi, et al.
Publicado: (2020) -
Phase 1b/2 trial of Ipilimumab, Nivolumab, and Ciforadenant (INC) (adenosine A2a receptor antagonist) in first-line advanced renal cell carcinoma
por: Beckermann, Kathryn, et al.
Publicado: (2023) -
Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021) -
Modeling Clear Cell Renal Cell Carcinoma and Therapeutic Implications
por: Wolf, Melissa M., et al.
Publicado: (2020)